Brokers Offer Predictions for CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($0.74) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.63) EPS, FY2026 earnings at $3.95 EPS, FY2027 earnings at $5.51 EPS, FY2028 earnings at $9.80 EPS and FY2029 earnings at $45.40 EPS.

Several other research firms have also issued reports on CRSP. Royal Bank of Canada lowered their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a report on Wednesday. The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $75.30.

CRISPR Therapeutics Stock Up 0.4 %

CRISPR Therapeutics stock opened at $43.49 on Friday. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The company’s 50-day moving average price is $42.06 and its 200-day moving average price is $46.25. The company has a market cap of $3.71 billion, a PE ratio of -15.37 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Capital Market Strategies LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at about $461,000. KBC Group NV lifted its position in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after buying an additional 57,696 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after buying an additional 22,583 shares in the last quarter. Geode Capital Management LLC grew its position in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares during the last quarter. Finally, State Street Corp raised its stake in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.